Table of Contents Author Guidelines Submit a Manuscript
Critical Care Research and Practice
Volume 2017, Article ID 3635609, 10 pages
Review Article

Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence

1Institute of Critical Care Medicine, Max Super Specialty Hospital, Saket, New Delhi 110017, India
2Department of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110060, India
3Department of Medical Affairs, Wockhardt Ltd., Wockhardt Towers, Mumbai 400051, India

Correspondence should be addressed to Salman Motlekar; moc.tdrahkcow@rakeltoms

Received 13 January 2017; Revised 7 April 2017; Accepted 29 May 2017; Published 6 July 2017

Academic Editor: Samuel A. Tisherman

Copyright © 2017 Suneel Kumar Garg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Polymyxin B has resurged in recent years as a last resort therapy for Gram-negative multidrug-resistant (MDR) and extremely drug resistant (XDR) infections. Understanding newer evidence on polymyxin B is necessary to guide clinical decision making. Here, we present a literature review of polymyxin B in Gram-negative infections with update on its pharmacology.